OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lee on the Potential Utility of Ibrutinib/Cirmtuzumab in MCL

February 16th 2021

Hun Ju Lee, MD, discusses the potential utility of ibrutinib in combination with cirmtuzumab in mantle cell lymphoma.

Dr. Hari on Mitigating Selinexor-Related Toxicities in Multiple Myeloma

February 16th 2021

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC

February 15th 2021

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

Dr. Mead on the Clinical Significance of the MURANO Trial in CLL

February 15th 2021

Monica D. Mead, MD, discusses the clinical significance of the phase 3 MURANO trial in chronic lymphocytic leukemia.

Dr. Jain on the Efficacy of Ibrutinib/Rituximab in MCL

February 15th 2021

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib plus rituximab in mantle cell lymphoma.

Off Our Chests: John Marshall, MD, and Liza Marshall Recount Her TNBC Journey

February 15th 2021

John Marshall, MD, and his wife, Liza, recount the challenging journey of Liza's triple-negative breast cancer (TNBC) diagnosis and how John's career as a gastrointestinal oncologist played into the caregiving process. The interview comes ahead of the release of their book, Off Our Chests, which goes further in depth with their experience.

Dr. Weiss on the FDA Approval of Trilaciclib in Small Cell Lung Cancer

February 12th 2021

Jared Weiss, MD, discusses the FDA approval of trilaciclib in small cell lung cancer.

Dr. Ruan on the Long-Term Benefits of Lenalidomide/Rituximab in MCL

February 12th 2021

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

Dr. Schiller on the Potential Utility of Asciminib in CML

February 12th 2021

Gary J. Schiller, MD, discusses the potential utility of asciminib in chronic myeloid leukemia.

Dr. Coveler on the Rationale to Evaluate NUC-3373 in Metastatic CRC

February 12th 2021

Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.

Dr. Grothey on Potential Combinations With Trastuzumab Deruxtecan in GI Malignancies

February 11th 2021

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

February 10th 2021

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

Dr. Schmidt on the Clinical Implications of AMG 420 in Multiple Myeloma

February 8th 2021

Timothy M. Schmidt, MD, discusses the clinical implications of AMG 420 in multiple myeloma.

Dr. Dhir on Diagnostic Challenges in Sarcoma

February 5th 2021

Aditi Dhir, MD, discusses the challenges of diagnosing patients with sarcoma.

Dr. Abramson on the FDA Approval of Liso-Cel in Refractory Large B-Cell Lymphoma

February 5th 2021

Jeremy S. Abramson, MD, discusses the FDA approval of lisocabtagene maraleucel in refractory large B-cell lymphoma.

Dr. Spencer on the Rationale to Evaluate Panobinostat in Multiple Myeloma

February 4th 2021

Andrew Spencer, MD, MBBS, FRACP, FRCPA, discusses the rationale to evaluate panobinostat in multiple myeloma.

Dr. Markman on the Need for Comparative Trials With PARP Inhibitors in Ovarian Cancer

February 3rd 2021

Maurie Markman, MD, discusses the need for comparative clinical trials with PARP inhibitors in ovarian cancer.

Dr. Meisel on Sequencing Considerations in First- and Second-Line HER2+ Breast Cancer

February 3rd 2021

Jane L. Meisel, MD, discusses sequencing considerations in the first- and second-line settings of HER2-positive breast cancer.

Dr. Dhakal on the Onset of CAR T-Cell Therapy–Induced CRS in Multiple Myeloma

February 3rd 2021

Binod Dhakal, MD, discusses the differences in onset of cytokine release syndrome with CAR T-cell therapies in multiple myeloma.

Dr. Gralow on the Integration on Precision Medicine Into Oncology

February 2nd 2021

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.